HealthQuill EU
Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood cancer therapy.
Drugs Health Pharma

J&J seeks approval for its blood cancer therapy in US, European Union

Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood.

Read More
Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without worsening the condition.
Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces live scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.

Read More
Israel has passed a law to ban the United Nations Relief and Works Agency from operating in the country after it earlier accused its employees of participation in the October 7 attacks — a move which came in for criticism from Western European leaders.
Drugs Health Medical

Israel bans UN relief agency, EU, Western European leaders slam move 

Israel has passed a law to ban the UN relief agency, UNRWA, from operating in the country after it earlier accused its employees.

Read More
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s drug to treat rare blood vessel disease gets EU nod

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

Read More
Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy medicine in a trial, according to a statement.
Drugs Health Pharma

Novo’s type 2 oral diabetic drug cuts heart diseases by 14% in a trial

Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.

Read More
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod

The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.

Read More
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.
Drugs Health Pharma

AstraZeneca’s asthma drug gets regulator’s approval in China

China’s drug regulator, the National Medical Products Association, has approved  AstraZeneca Plc’s asthma drug.

Read More
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic adults with obesity, according to a statement from the EU regulator.
Drugs Health Pharma

Wegovy gets EU regulator backing on lowering heart risks in obese people

The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.

Read More
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
Drugs Health Pharma

AstraZeneca acquires France’s Amolyt Pharma for $1.05 billion

British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.

Read More
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according to a company statement.
Drugs Health Pharma

FDA approves AstraZeneca’s type-2 diabetes drug in US market

AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.

Read More